The Food and Drug Administration, the US medicines regulator, ordered labeling changes on November 9. It includes semaglutide, sold as Ozempic and Wegovy, and tirzepatide, sold as Zepbound and Mounjaro.
Daylight Post found a difference in the notices’ scope. Britain’s February 5 review covered semaglutide, not other medicines in the group.
The European Medicines Agency, which assesses medicines for the European Union, issued its notice in June 2025. It also concerned semaglutide. It described the eye condition as a very rare side effect.
Those earlier reviews did not assess every medicine in the new US warning. A broader warning does not establish an equal risk for every drug.
Different names, different medicines
These medicines are often called GLP-1 drugs. They copy the action of a hormone released after eating, helping control appetite and blood sugar. Some are prescribed for diabetes, others for weight management, and some have more than one approved use. They are treatments for medical conditions, rather than simply products for losing a few pounds.
A brand name is the name on the package. The active ingredient is the drug inside it. Different brands can contain the same ingredient. That is why it matters whether a safety notice names a brand, one ingredient or the wider group of medicines.
Rare does not mean harmless
The condition is called NAION. It damages the optic nerve, which carries visual information from the eye to the brain, when blood flow to its front part falls. Sight can become blurred or cloudy, often suddenly and without pain. Diabetes itself also raises the risk, making it harder to separate the effects of illness and treatment.
The European review estimated about one additional case for every 10,000 people treated with semaglutide for a year, based on studies of adults with type 2 diabetes. That describes a small added risk in a specific group. It is not a prediction that one in every 10,000 users of any weight-loss medicine will lose their sight.
What the warning asks patients to do
Permanent sight loss is possible. The US notice tells patients to contact a health professional immediately about sudden sight loss, blind spots or other changes in vision. If NAION occurs, patients should discuss with their clinician whether to continue treatment or stop.
The British regulator also advises speaking to a health professional before switching between these medicines. They differ in strength, how they are used and which conditions they treat. Changing brands is not the same as checking whether a new treatment is suitable.